Repurposing SARS-CoV Antibodies to Design Cocktails to Neutralize All Known SARS-CoV2 Variants

In the last 10 years monoclonal antibodies (mAbs) have emerged as the leading targeted therapy for cancer, autoimmune diseases, Alzheimer's disease, and viral infections. Antibody therapy has several advantages over vaccination. First, a shorter time is required for clinical testing than is required in developing a vaccine. In addition, antibody therapy provides immediate protection and the opportunity to administer Abs at higher levels than in a natural immune response. However, it is a slow and laborious process to raise neutralizing Abs by immunization for each virus type and subtype. In this work we are using a combination of computational modeling and antibody library screening to rapidly adapt SARS-CoV-neutralizing antibodies to SARS-CoV2. In particular we will adapt SARS-CoV-neutralizing antibodies 80R, S230, and F26G19 to neutralize SARS-CoV-2.